LONDON, May 27 (Reuters) - AstraZeneca said on
Friday U.S. regulators would not approve its new drug for high
potassium levels at present due to a manufacturing issue,
dealing a blow to a product acquired when it bought ZS Pharma
for $2.7 billion last year.
Read more
No comments:
Post a Comment